Some Characteristics of Mouse Platelet Aggregation and a Comparison of the Activity of a Range of Compounds in Mouse and Human Platelet-Rich Plasma in Vitro

Summary

Collagen-induced platelet aggregation in mouse citrated platelet-rich plasma (PRP) was associated with 5-hydroxytryptamine (5-HT) release and degranulation. Adenosine 5’-diphosphate (ADP) induced monophasic and reversible aggregation with no degranulation. Mouse platelets gave no response to adrenaline but changed shape and sometimes aggregated in response to 5-HT. Both amines potentiated the effect of ADP. The respective potencies of prostaglandin E₁, papaverine, VK 774, BL 3459 and adenosine as inhibitors of ADP-induced aggregation were similar in mouse and human PRP. Although ticlopidine had similar activity in the two species, aspirin and flurbiprofen were considerably less potent in mouse than human PRP as inhibitors of collagen-induced aggregation. It is suggested that collagen-induced aggregation of mouse platelets in vitro occurs by a mechanism largely independent of arachidonic acid metabolites.

Keywords

Mouse - Platelet - Aggregation - Inhibitors

• References

• 1 Nishizawa EE, Wynalda DJ, Suydam DE, Sawa TR, Schultz JK. Collagen-induced pulmonary thromboembolism in mice. Thromb Res 1972; 1: 233-242
• 2 Kohler C, Wooding W, Ellenbogen L. Intravenous arachidonate in the mouse: a model for the evaluation of anti-thrombotic drugs. Thromb Res 1976; 9: 67-80
• 3 Tomikawa M, Ashida S, Kakihata K, Abiko Y. Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitor. Thromb Res 1978; 12: 1157-1164
• 4 O’Bryan BS, Fishel CW. Aggregation of platelets of normal and Bordetella pertussis vaccinated mice by ATP, ADP and sodium fluoride. Int Arch Allergy 1971; 41: 514-530
• 5 Klein TW, Szentivanyi A, Fishel CW. Effect of serotonin on platelets of normal and B. pertussis-injected mice. Proc Soc exp Biol Med 1974; 147: 681-686
• 6 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond) 1962; 194: 927-929
• 7 Nunn B, James FJ. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo; comparison with naproxen. Br J Clin Pharmac 1980; 9: 239-245
• 8 Sixma JJ, Linssen WH, Geuze HJ. Glutaraldehyde fixation of human blood platelets. Thromb Diath haemorrh (Stuttg) 1972; 26: 272-277
• 9 Beverung WN, Partyka RA. 6-Methyl, 1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolin-2-one, a potent inhibitor of ADP-induced platelet aggregation. J Med Chem 1975; 18: 224-225
• 10 Rozenberg MC, Holmsen H. Adenine nucleotide metabolism of blood platelets. II. Uptake of adenosine and inhibition of ADP-induced platelet aggregation. Biochim Biophys Acta 1968; 155: 342-352
• 11 Sinakos Z, Caen JP. Platelet aggregation in mammalians (human, rat, rabbit, guinea pig, horse, dog). A comparative study. Thrombos Diath haemorrh (Stuttg) 1967; 17: 099-111
• 12 Donner L, Houskova J. Some properties of blood platelets in animal species. Folia Haematol (Leipzig) 1972; 98: 296-302
• 13 Macmillan DC, Sim AK. A comparative study of platelet aggregation in man and laboratory animals. Thrombos Diath haemorrh (Stuttg) 1970; 24: 385-394
• 14 Constantine JW. Aggregation of guinea pig platelets by adenosine diphosphate. Nature (Lond) 1966; 210: 162-164
• 15 Mills DCB. Platelet aggregation and platelet nucleotide concentration in different species. Symp Zool Soc London 1970; 27: 99-107
• 16 O’Brien JR. A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J Clin Path 1964; 17: 275-281
• 17 Ardlie NG, Glew G, Schwartz CJ. Influence of catecholamines on nucleotide-induced platelet aggregation. Nature (Lond) 1966; 212: 415-417
• 18 Mills DCB, Roberts GC K. Effects of adrenaline on human blood platelets. J Physiol (Lond) 1967; 193: 443-453
• 19 Baumgartner HR, Born GV R. Effects of 5-hydroxytryptamine on platelet aggregation. Nature (Lond) 1968; 218: 137-141
• 20 Yu SK, Latour JG. Potentiation by α and inhibition by β-adrenergic stimulations of rat platelet aggregation. A comparative study with human and rabbit platelets. Thrombos Haemostas (Stuttg) 1977; 37: 413-421
• 21 Holmsen H. Classification and possible mechanisms of action of some drugs that inhibit platelet aggregation. Ser Haematol 1976; 8: 50-80
• 22 Tang SS, Frojmovic MM. The effects of two new anti-thrombotic agents (imidazoquinazolinones) on platelet shape and aggregation. Thrombos Haemostas (Stuttg) 1977; 38: 95
• 23 Cuthbertson WF J, Mills DCB. Some factors influencing platelet clumping. J Physiol (Lond) 1963; 169: 9P-10P
• 24 Slater SD, Turpie AG G, Douglas AS, McNicol GP. Effect in vitro on platelet function of two compounds developed from the pyrimido-pyrimidines. J clin Path 1972; 25: 427-432
• 25 Sullivan JM, Harken DE, Gorlen R. Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation 1969; 39-40 Suppl. 1: 149-153
• 26 Anturane Reinfarction Trial Research Group. Sulphinpyrazone in the prevention of cardiac death after myocardial infarction. New Engl J Med 1978; 298: 289-295
• 27 Zucker MB, Peterson J. Inhibition of adenosine-diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc exp Biol Med 1968; 127: 547-551
• 28 Nishizawa EE, Wynalda DJ, Suydam DE, Molony BA. Flurbiprofen, a new potent inhibitor of platelet aggregation. Thromb Res 1973; 3: 577-588
• 29 Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33-67
• 30 Malmsten C, Hamberg M, Svensson J, Samuelsson B. Physiological role of an endoperoxide in human platelets: haemostatic defect due to platelet cyclo-oxygenase deficiency. Proc Nat Acad Sci 1975; 72: 1446-1450
• 31 Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharm Therap 1975; 18: 485-490
• 32 De GaetanoG, Miragliotta G, Roncucci R, Lansen J, Lambelin G. Suloctidil: a novel inhibitor of platelet aggregation in human beings. Thromb Res 1976; 8: 361-371